Table 1.
Baseline characteristics
| VTA+ (n = 59) | VTA− (n = 152) | P | |
|---|---|---|---|
| Age (years), mean ± SD | 47.7 ± 16.1 | 47.9 ± 17.0 | 0.946 |
| Male, n (%) | 49 (83.1) | 125 (82.4) | 0.889 |
| LVEF (%), mean ± SD | 43.8 ± 13.2 | 42.3 ± 15.5 | 0.517 |
| Primary prevention implant, n (%) | 21 (35.6) | 66 (43.7) | 0.283 |
| Hypertension, n (%) | 22 (37.3) | 51 (39.2) | 0.799 |
| Diabetes, n (%) | 3 (5.1) | 24 (18.5) | 0.015 |
| CKD, n (%) | 5 (8.5) | 21 (16.2) | 0.156 |
| Substrate | |||
| Ischaemic cardiomyopathy, n (%) | 19 (32.2) | 49 (32.2) | 0.996 |
| DCM, n (%) | 9 (15.3) | 28 (18.4) | 0.587 |
| HCM, n (%) | 3 (5.1) | 11 (7.2) | 0.573 |
| Brugada, n (%) | 2 (3.4) | 9 (5.9) | 0.458 |
| ARVC, n (%) | 6 (10.2) | 11 (7.2) | 0.482 |
| Idiopathic VF, n (%) | 8 (13.6) | 19 (12.5) | 0.836 |
| Valvular cardiomyopathy, n (%) | 0 | 2 (1.3) | 0.376 |
| LQTS, n (%) | 0 | 6 (3.9) | 0.121 |
| Myocarditis, n (%) | 4 (6.8) | 6 (4.0) | 0.385 |
| Other, n (%) | 8 (13.6) | 11 (7.2) | 0.150 |
| S-ICD placement details | |||
| Two-incision technique, n (%) | 54 (91.5) | 139 (92.1) | 0.900 |
| Inter-muscular placement, n (%) | 43 (72.9) | 118 (78.2) | 0.418 |
| PRAETORIAN score available, n (%) | 51 (86.4) | 122 (80.2) | 0.296 |
| Low risk (<90)a, n (%) | 47 (92.1) | 116 (95.1) | 0.452 |
| S-ICD programming details | |||
| Conditional zone (b.p.m.), median (IQR) | 200 (200–220) | 200 (190–220) | 0.385 |
| Shock zone (b.p.m.), median (IQR) | 240 (230–250) | 240 (230–250) | 0.189 |
| Vector programming | |||
| Primary, n (%) | 38 (64.4) | 92 (60.5) | 0.603 |
| Secondary, n (%) | 14 (23.7) | 44 (28.9) | 0.446 |
| Alternative, n (%) | 7 (11.8) | 16 (10.5) | 0.780 |
| SMART Pass algorithm, n (%) | 51 (86.4) | 120 (78.9) | 0.212 |
| Medical treatment | |||
| Beta-blockers, n (%) | 44 (74.6) | 99 (65.1) | 0.187 |
| IC, n (%) | 2 (3.4) | 2 (1.3) | 0.321 |
| Amiodarone, n (%) | 14 (20.4) | 31 (23.7) | 0.596 |
| Mexiletine, n (%) | 2 (3.4) | 1 (0.7) | 0.132 |
| Sotalol, n (%) | 3 (5.1) | 6 (3.9) | 0.714 |
| Patients experiencing at study inclusion | |||
| Appropriate shock(s), n (%) | 48 (81.3) | 130 (85.5) | 0.454 |
| Num. of appropriate shocks, median (IQR) | 2 (1–4) | 2 (1–3) | 0.590 |
| Hospitalizations for monomorphic VT(s), n (%) | 11 (18.7) | 23 (15.1) | 0.533 |
Statistically significant P values have been boldened.
ARVC, arrhythmogenic right ventricular cardiomyopathy; CKD, chronic kidney disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IC, class Ic anti-arrhythmic drugs; IQR, inter-quartile range; LVEF, left ventricular ejection fraction; LQTS, long-QT syndrome; SD, standard deviation; S-ICD, subcutaneous implantable cardioverter defibrillator; VT, ventricular tachycardia; VF, ventricular fibrillation.
aPercentages are calculated on the total of patients for which a PRAETORIAN Score is available.